Atezolizumab + Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41378717/
First-line atezolizumab combination therapies were approved for the treatment of metastatic non-small cell lung cancer (NSCLC) based on results from the global phase 3 trials IMpower130, IMpower132, and IMpower150. These...
J-TAIL-2 demonstrated that atezolizumab plus chemotherapy combinations achieved real-world survival and safety outcomes in Japanese advanced NSCLC patients comparable to pivotal IMpower trials, including effectiveness in broader “IMpower-unlike” clinical populations.
Co-occurrence of interstitial lung disease and pulmonary embolism as adverse events of adjuvant osimertinib treatment for EGFR mutant non-small cell lung cancer: a case report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40610986/
We encountered a case of interstitial lung disease and pulmonary embolism occurring simultaneously as adverse events during adjuvant osimertinib treatment. In patients with osimertinib-induced interstitial lung disease, particularly when respiratory...
This case report describes simultaneous interstitial lung disease and pulmonary embolism during adjuvant osimertinib therapy for EGFR-mutant NSCLC, highlighting the need to evaluate persistent respiratory symptoms for thromboembolic complications.
Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40179330/
Taletrectinib showed a high response rate with durable responses, robust IC activity, prolonged PFS, favorable safety, and low rates of neurologic adverse events in TKI-naïve and pretreated patients.
Taletrectinib shows high response rates, durable efficacy, strong CNS activity, and manageable safety in ROS1+ NSCLC, including TKI-naïve and pretreated patients, supporting its role as an effective next-generation therapy.
Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40849659/
This review provides a comprehensive synthesis of current knowledge on immunotherapy resistance in non-small cell lung cancer (NSCLC), a disease that accounts for approximately 85% of all lung cancer cases...
Review outlines immunotherapy resistance in NSCLC driven by tumor-intrinsic and microenvironmental factors; highlights microbiome influence and supports combination, biomarker-guided, and immune-restoring strategies to improve treatment response and personalization.
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40446626/
These final analyses demonstrate the durable, long-term OS and response benefit with first-line nivolumab plus ipilimumab with chemotherapy over chemotherapy in patients with metastatic NSCLC, regardless of tumor PD-L1 expression,...
Six-year CheckMate 9LA results show nivolumab plus ipilimumab with chemotherapy provides durable survival and response benefits over chemotherapy in metastatic NSCLC, independent of PD-L1 status, histology, or mutations.